Catalyst Trader

What It Is

Ray Blanco's Catalyst Trader is a biotech/microcap investment research newsletter from Paradigm Press, built around trading small companies ahead of binary "catalyst" events.

Core Mechanism / Strategy

• Identifies tiny microcap companies facing imminent catalysts — FDA approvals, clinical-trial data releases, buyouts, and major partnerships
• Recommends entering before the catalyst event to capture the move as a stock goes from obscurity to mainstream awareness
• Uses insider buying and institutional accumulation as confirmation signals
• Represents a shift from Blanco's prior buy-and-hold approach toward shorter-duration, event-driven trades

What the Subscriber Gets

• Urgent special report (featured oncolytic-virus cancer stock name, ticker, and analysis)
• At least one new recommendation per month, plus urgent flash alerts on new catalysts
• A "Catalyst Calendar" of upcoming catalyst events
• CEO interview access with Q&A
• Weekly updates covering open positions and a subscriber Q&A section

Differentiators / Positioning

• Lead thesis built on a novel oncolytic-virus mechanism (a modified virus targeting cancer cells)
• Positioned as leveling the playing field — using publicly disclosed FDA dates so Main Street can act ahead of Wall Street
• Celebrity endorsement from James Altucher; led by Ray Blanco with host Aaron Gensler (VP of Research, Paradigm Press)

Target Audience

• Altucher/Paradigm subscribers; self-directed investors with brokerage accounts
• Main Street investors who feel disadvantaged vs. Wall Street; those personally touched by cancer

Offer Structure

• $1,995/year, anchored against a $5,000 standard price (~60% off)
• Limited to the first 290 subscribers, justified by the microcap's low liquidity
• Performance guarantee: a free bonus year if the featured stock fails to 10x in 12 months (service extension, not a cash refund)

Last enriched by FID from 1 promo(s).

Parent Company: Paradigm Press

Ray Blanco's Catalyst Trader is a biotech/microcap investment research newsletter from Paradigm Press, built around trading small companies ahead of binary "catalyst" events.

• Identifies tiny microcap companies facing imminent catalysts — FDA approvals, clinical-trial data releases, buyouts, and major partnerships
• Recommends entering before the catalyst event to capture the move as a stock goes from obscurity to mainstream awareness
• Uses insider buying and institutional accumulation as confirmation signals
• Represents a shift from Blanco's prior buy-and-hold approach toward shorter-duration, event-driven trades

• Urgent special report (featured oncolytic-virus cancer stock name, ticker, and analysis)
• At least one new recommendation per month, plus urgent flash alerts on new catalysts
• A "Catalyst Calendar" of upcoming catalyst events
• CEO interview access with Q&A
• Weekly updates covering open positions and a subscriber Q&A section

• Lead thesis built on a novel oncolytic-virus mechanism (a modified virus targeting cancer cells)
• Positioned as leveling the playing field — using publicly disclosed FDA dates so Main Street can act ahead of Wall Street
• Celebrity endorsement from James Altucher; led by Ray Blanco with host Aaron Gensler (VP of Research, Paradigm Press)

• Altucher/Paradigm subscribers; self-directed investors with brokerage accounts
• Main Street investors who feel disadvantaged vs. Wall Street; those personally touched by cancer

• $1,995/year, anchored against a $5,000 standard price (~60% off)
• Limited to the first 290 subscribers, justified by the microcap's low liquidity
• Performance guarantee: a free bonus year if the featured stock fails to 10x in 12 months (service extension, not a cash refund)

Last enriched by FID from 1 promo(s).

• 2026-07-04 — Auto-seeded by FID from promo activity.